Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer (Q35640641)

From Wikidata

Jump to navigation Jump to search

scientific article published on December 2003

Language	Label	Description	Also known as
English	Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer	scientific article published on December 2003

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

Europe PubMed Central

Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Nancy A Dawson

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Susan F Slovin

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

language of work or name

0 references

publication date

1 December 2003

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

62 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

102-118

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Clinical states in prostate cancer: toward a dynamic model of disease progression

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Vaccines as treatment strategies for relapsed prostate cancer: approaches for induction of immunity

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

DNA vaccines: a review

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Induction of a cytotoxic T lymphocyte (CTL) response to plasmid DNA delivered via Lipodine liposomes

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Epitopic structure of Tn glycophorin A for an anti-Tn antibody (MLS 128)

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Study of the expression and function of the tumour-associated antigen CaMBr1 in small cell lung carcinomas

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Breast cancer immunotherapy: current status and future prospects

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Enhancement of DNA vaccine potency using conventional aluminum adjuvants

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

The dendritic cell system and its role in immunogenicity

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

A Fully Synthetic Globo H Carbohydrate Vaccine Induces a Focused Humoral Response in Prostate Cancer Patients: A Proof of Principle

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Gene therapy approaches in urologic oncology.

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Cyclooxygenase-2: a therapeutic target

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Inhibition of cyclooxygenase-2 gene expression by p53.

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Role of cyclooxygenases in angiogenesis

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Many actions of cyclooxygenase-2 in cellular dynamics and in cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Sulindac inhibits activation of the NF-kappaB pathway

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Expression of cyclooxygenase-2 in prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

The biology of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Non-steroidal anti-inflammatory drugs and prostate cancer progression

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Inhibition of nuclear factor-kappaB by a nitro-derivative of flurbiprofen: a possible mechanism for antiinflammatory and antiproliferative effect

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines.

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

The role of vitamin D in prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Vitamin D receptor: a potential target for intervention

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1α,24‐dihydroxyvitamin D2

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Vitamin D-related therapies in prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Vitamin D3 analogue inhibits keratinocyte growth factor signaling and induces apoptosis in human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

Construction of fowlpox virus vectors with intergenic insertions: expression of the beta-galactosidase gene and the measles virus fusion gene.

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.10.027

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.UROLOGY.2003.10.027

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35640641&oldid=2049305452"